Every Form 4 that Dermata Therapeutics, Inc. Warrant (DRMAW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DRMAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DRMAW filings page.
Dermata Therapeutics, Inc. (DRMA) reported that director and executive officer Gerald T. Proehl, through affiliated entities, acquired multiple warrant positions and common shares in a private placement exempt under Rule 16b-3(d)(1). Proehl Investment Ventures LLC received 1,360,544 Series E and 1,360,544 Series F warrants and 1,360,544 pre-funded warrants, each for common stock at exercise prices of $1.47 (Series E/F) and $0.001 (pre-funded). A family trust acquired 170,068 Series E, 170,068 Series F warrants and 170,068 common shares, increasing its indirect holdings to 292,631 shares. The warrants become exercisable only after stockholder approval and are subject to a 9.99% beneficial ownership cap, and the reporting person disclaims beneficial ownership beyond pecuniary interest.
Dermata Therapeutics, Inc. (DRMA) reported that its SVP and CFO, Kyri K. Van Hoose, acquired securities in a private placement. She acquired 102,040 shares of common stock and now directly holds 232,463 common shares. In the same transaction, she received a Series E Warrant and a Series F Warrant, each for 102,040 underlying common shares at an exercise price of $1.47 per share. The common stock and accompanying warrants were purchased together at $1.47 per unit. The warrants become exercisable on the effective date of required stockholder approval, are capped at 9.99% beneficial ownership, and expire five years (Series E) and two years (Series F) after that approval.
Dermata Therapeutics director Kathleen D. Scott reported a small open-market sale of common stock. She sold 11 shares of Dermata Therapeutics, Inc. common stock in an open-market transaction at a price of $1.1901 per share. After this sale, she held no shares directly but reported indirect ownership of 1 share held by the Scott 2008 Trust Dated 3/28/08.
Dermata Therapeutics, Inc. senior vice president of regulatory affairs Maria E. Bedoya-Toro Munera bought 1,000 shares of common stock in an open-market transaction at $1.27 per share on February 17, 2026. Following this purchase, she holds 1,012 shares directly and 34 shares indirectly through the Munera Family Trust.